Stem definition | Drug id | CAS RN |
---|---|---|
acridine derivatives | 2338 | 83-89-6 |
Dose | Unit | Route |
---|---|---|
0.30 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 28.57 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 12.50 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 45 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 120 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1933 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lupus vasculitis | 199.74 | 58.21 | 26 | 479 | 543 | 63487974 |
Lupus nephritis | 157.97 | 58.21 | 26 | 479 | 2813 | 63485704 |
Mitral valve incompetence | 107.87 | 58.21 | 26 | 479 | 19568 | 63468949 |
Febrile neutropenia | 61.84 | 58.21 | 26 | 479 | 118423 | 63370094 |
Gastrointestinal disorder | 59.27 | 58.21 | 26 | 479 | 131213 | 63357304 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lupus vasculitis | 207.70 | 52.13 | 26 | 438 | 548 | 79743376 |
Lupus nephritis | 164.65 | 52.13 | 26 | 438 | 2982 | 79740942 |
Mitral valve incompetence | 106.27 | 52.13 | 26 | 438 | 28539 | 79715385 |
Gastrointestinal disorder | 68.99 | 52.13 | 26 | 438 | 122179 | 79621745 |
Febrile neutropenia | 53.04 | 52.13 | 26 | 438 | 230973 | 79512951 |
None
Source | Code | Description |
---|---|---|
ATC | P01AX05 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES Other agents against amoebiasis and other protozoal diseases |
MeSH PA | D000871 | Anthelmintics |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000923 | Anticestodal Agents |
MeSH PA | D000962 | Antimalarials |
MeSH PA | D000969 | Antinematodal Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D000980 | Antiplatyhelmintic Agents |
MeSH PA | D000981 | Antiprotozoal Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
CHEBI has role | CHEBI:38068 | antimalarials |
CHEBI has role | CHEBI:77402 | EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Giardiasis | indication | 58265007 | DOID:10718 |
Pneumothorax | off-label use | 36118008 | |
Discoid lupus erythematosus | off-label use | 200938002 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.19 | Basic |
pKa2 | 8.11 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Alpha-2A adrenergic receptor | GPCR | Ki | 6.07 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.54 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.12 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.08 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.35 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.46 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.45 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.47 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.58 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.56 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.57 | DRUG MATRIX | |||||
Aldehyde oxidase | Enzyme | IC50 | 5.48 | WOMBAT-PK | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.25 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.99 | DRUG MATRIX | |||||
Acetylcholinesterase | Enzyme | IC50 | 5.57 | DRUG MATRIX | |||||
Major prion protein | Surface antigen | EC50 | 6.52 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.48 | CHEMBL | |||||
Trypanothione reductase | Enzyme | Ki | 4.72 | CHEMBL | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 5.72 | DRUG MATRIX | |||||
Cholinesterase | Enzyme | IC50 | 5.35 | CHEMBL | |||||
Riboflavin-binding protein | Unclassified | Kd | 6.58 | CHEMBL | |||||
Cyclooxygenase | Enzyme | IC50 | 4.49 | CHEMBL | |||||
Bacterial DNA-directed RNA polymerase | Enzyme | IC50 | 4.70 | CHEMBL | |||||
Phospholipase A2 group 1B | Enzyme | IC50 | 4 | CHEMBL | |||||
Phospholipase A2 group 1B | Enzyme | IC50 | 4 | CHEMBL | |||||
Major prion protein | Unclassified | IC50 | 7.02 | CHEMBL |
ID | Source |
---|---|
4019924 | VUID |
N0000148009 | NUI |
D08179 | KEGG_DRUG |
4018230 | VANDF |
4019924 | VANDF |
C0034403 | UMLSCUI |
CHEBI:8711 | CHEBI |
QUN | PDB_CHEM_ID |
CHEMBL7568 | ChEMBL_ID |
DB01103 | DRUGBANK_ID |
237 | PUBCHEM_CID |
10172 | IUPHAR_LIGAND_ID |
6151-30-0 | SECONDARY_CAS_RN |
82092 | RXNORM |
10011 | MMSL |
d00158 | MMSL |
002937 | NDDF |
004871 | NDDF |
350225009 | SNOMEDCT_US |
387363006 | SNOMEDCT_US |
387445007 | SNOMEDCT_US |
D011796 | MESH_DESCRIPTOR_UI |
CHEMBL554190 | ChEMBL_ID |
CHEMBL2105615 | ChEMBL_ID |
CHEMBL556980 | ChEMBL_ID |
396 | INN_ID |
H0C805XYDE | UNII |
None